VITTA TRIAL – safety and performance at 3-year follow-up after implantation of the VIVERE® aortic bioprosthesis
At 36 months, VIVERE® demonstrated favorable valve-related safety and efficacy, with low valve-related mortality, stable hemodynamics, and sustained functional improvement.
Authors
- Luiz Carlos Bettiati
- Davi Jean Buoro Cassano
- Caio Eduardo Gullo
- João Carlos Ferreira Leal
Institutions
- Hospital São Vicente de Paulo (BR)
- Beneficência Portuguesa de São Paulo (BR)
- Hospital Nossa Senhora da Conceição (BR)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2026-02-18
- DOI
- https://doi.org/10.3389/fcvm.2026.1765211
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00